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Abstract
Although hormone receptors discordance in the 
evolution of breast cancer was extensively studied, 
it almost always has been treated as a dichotomous 
variable, disregarding their absolute values. 
The degree, the direction and the significance 
of quantitative variations in time in the level 
of expression of estrogen receptors (ER) and 
progesterone receptors (PR) are largely unknown. 
We performed a retrospective analysis of 
quantitative changes in the level of ER and 
PR in paired samples from either primary or 
recurrent lesion from the same patient in two 
separated points in time. ER and d PR expression 
was recorded as the percentage of staining cells. 
Subgroups analyses were not pre-planned.
Sixty-eight females with breast cancer of any 
stage were included. Wilcoxon signed-rank test 
indicated a statistically significant reduction in 
the ER expression between first and second ER 
determination (Z=-2.75, r=-0.23, p=0.006). For PR, 
the difference was not statistically significant. In 
the subgroup analyses, after Bonferroni correction, 
only exposure to endocrine treatment, tissue 
obtained by surgery and age >40 years were 
significantly associated with the decrease in the 
ER expression level. 
Even though random error and technical issues 
are likely the main sources of the ER variability, 
the results of our study suggest a trend to a 
decrease in ER expression, in the relationship with 
tissue sampling methodology and/or exposure to 
endocrine therapy. 
Key words: estrogen receptors, hormone 
receptors, quantitative variation, endocrine 
therapy, tissue sampling method
Resumen 
Si bien se estudió ampliamente la discordancia 
de los receptores hormonales en la evolución 
del cáncer de mama, casi siempre se trató como 
una variable dicotómica, sin tener en cuenta 
sus valores absolutos. El grado, la dirección y la 
importancia de las variaciones cuantitativas en el 
tiempo en el nivel de expresión de los receptores 
de estrógeno (RE) y los receptores de progesterona 
(RP) son en gran parte desconocidos.
Realizamos un análisis retrospectivo de los cambios 
cuantitativos en el nivel de RE y RP en muestras 
pareadas de lesiones primarias o recurrentes del 
mismo paciente en dos puntos separados en el 
tiempo. La expresión de RE y d RP se registró como 
el porcentaje de células teñidas. Los análisis de 
subgrupos no fueron planificados previamente.
Se incluyeron 68 mujeres con cáncer de mama de 
cualquier estadio. La prueba de rango con signo de 
Wilcoxon indicó una reducción estadísticamente 
significativa en la expresión de RE entre la 
primera y la segunda determinación de RE 
(Z=-2.75, r=-0.23, p=0.006). Para RP, la diferencia 
no fue estadísticamente significativa. En los 
análisis de subgrupos, después de la corrección 
de Bonferroni, sólo la exposición al tratamiento 
endocrino, el tejido obtenido mediante cirugía y la 
edad >40 años se asociaron significativamente con 
la disminución en el nivel de expresión de RE.
A pesar de que el error aleatorio y los problemas 
técnicos son probablemente las principales 
fuentes de la variabilidad de la RE, los resultados 
de nuestro estudio sugieren una tendencia a 
una disminución en la expresión de la RE, en 
la relación con la metodología de muestreo de 
tejidos y/o la exposición a la terapia endocrina.
Palabras clave: receptores de estrógeno, 
receptores de hormonas, variación cuantitativa, 
terapia endocrina, método de muestreo de tejido
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Introduction
Biomarker status determination plays an 
essential role in clinical decision-making in 
patients with invasive breast cancer. Estrogen 
receptors (ER) and progesterone receptors (PR) 
measurement are mandatory at the time of the 
initial diagnosis and it is recommended, when 
feasible, in recurrent lesions1,2. Several studies 
investigated the discordance in ER and PR 
expression between immunohistochemically 
(IHC) assessed tissue from primary tumors 
and paired second primary, loco-regional and 
metastatic recurrences with dissimilar results3-7. 
In a meta-analysis of 39 studies, published 
by Schrijver et al, after the mean follow-up of 
51 months, pooled estimates of ER conversion 
rates from positive to negative and vice versa 
both were around 22%. Pooled estimates of 
PR conversion rates from positive to negative 
were 49% and from negative to positive 16%, 
making apparent a trend toward lesser hormone 
receptors expression8. 
However, all of these studies treated hormone 
receptors expression as a binary variable 
(positive/negative) providing few insights, if 
any, into the relation of the phenomenon with 
the intrinsic tumor characteristics or extrinsic 
environmental factors, such as treatment 
exposure. We are not aware of any relevant study 
addressing quantitative changes in hormone 
receptors expression in a comprehensive 
manner. Thus, although in the study by Dieci 
et al, reporting on ER and PR conversion rates, 
quantitative absolute changes in ER and PR 
were displayed as waterfall plots, data analyses 
were not provided7. The lack of interest in ER 
and PR expression as a quantitative continuous 
variable is likely due to issues of assay 
reproducibility and lack of the uncontroversial 
demonstration of a strong relationship between 
quantitative hormone receptor expression and 
clinically important outcomes9,10. Nevertheless, 
as more protracted adjuvant endocrine 
treatments became more utilized and new drugs 
for advanced hormone receptor-positive breast 
cancer more universally available, the practical 
relevance of the quantitative hormone expression 
might increase. Also, the study of quantitative 
variations in ER and PR may contribute to a 
better understanding of the time behavior of the 
neoplastic process.
We aimed to study quantitative changes in 
ER and PR expression in paired samples 
corresponding to two separate points in time and 
their relationship with some clinical features 
and treatment exposure.
Materials and methods
We performed a retrospective pairwise 
comparison of the level of ER and PR expression 
in breast cancer. Patients have been retrieved 
from a prospectively acquired database in the 
Department of Pathology at Hospital Dr. Juan A. 
Fernández. We included females of any age with 
the histopathologic diagnosis of invasive breast 
cancer admitted between October 10th, 2010 and 
October 17th, 2017. Metastases to the breast, 
mesenchymal and lymphoid tumors were the 
exclusion criteria. Selected patients were further 
screened for the availability of quantitative data 
on the level of expression of ER and PR, either 
on biopsies or surgical specimens of primary 
tumor or metastases in two separated time 
points. The cut-point between synchronous and 
metachronous lesions has been set in six months. 
Initially, we had planned to screen all eligible 
patients. However, recruitment was prematurely 
closed after 213 patients have been included by 
a non-probabilistic convenience sampling. The 
study selection process is shown in Figure 1.
Figure 1. Flow chart of the study selection process
Patients potentially  
eligible for study.  
N=401
Patients who met  
eligibility criteria.  
N=401
Selected as a result of 
convenience sampling.  
N=213
Patients with biomarker status 
available in two time points 
and included in pairwise 
comparisons.  
N=68
ER N= 68 PR N= 68
Patients who met  
exclusion criteria.  
N=0
 Excluded as a result of 
convenience sampling.  
N=188
Further excluded because of 
ER and PR status available 
in less than twotime points. 
N=145
From non-electronic clinical charts of selected 
patients, we extracted data on ER and PR status 
and treatment exposure. Information on primary 
antibody and IHC assay protocol was absent in 
almost all clinical charts and was not recorded. 
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Hormone receptor expression was treated 
as a continuous variable and recorded as a 
percentage of staining cell. The main outcome 
was quantitative changes in ER expression in 
percentage points between two time points: 
∆ER=ER2-ER1, ∆PR=PR2-PR1. Continuous 
variables were not normally distributed and 
data was paired. Thus, to test against the null 
hypothesis that there is no difference between 
the percentage of staining cells in two time points 
we performed a two-tailed Wilcoxon signed-rank 
test. Subgroup analyses were not pre-planned. 
Bonferroni correction for multiple comparisons 
was applied, except for those cases in which 
p-values could not be accurately calculated 
because of the small N. As an effect size measure 
we used r statistic (r=Z/ √N)11. The effect size 
was graded as small if r was between 0.10 and 
0.39, medium if r was in the range 0.40-0.59, 
and large if r value was 0.60 or higher, as it was 
suggested by Mangiafico11. Spearman´s rank 
correlation was used for strength of association 
measurements. The degree of correlation was 
interpreted following the guidance provided by 
Mukaka12. Data on time period between hormone 
receptor analyses was log-transformed, but 
continued to follow a non-normal distribution. 
Thus, the Kruskal-Wallis test was performed to 
examine the relationship between ∆ER and ∆RP 
and time interval. All tests were done at alpha 
level 0.05.
For grouping purposes, we defined as a high 
ER o PR expression levels between 81% and 
100%, intermediate - those between 21 and 
80%, low-between 1% and 20%, and null-0%. 
Based on this classification we put forward 
a model of the ER transition between groups. 
Simple descriptive statistics were performed in 
Microsoft Excel©. For Wilcoxon signed-ranked 
test and Kruskal-Wallis test we used the online 
tool Social Science Calculator13. 
Results
Patient selection process is shown in Figure 1. 
From 401 eligible patients, 213 were included 
by a convenience sampling. Of them, after 
the screening for pairwise pathology reports 
availability, we selected 68. The mean age was 
51.7 (SD: +/-14.4) years. The initial stage was I in 
10.5%, II in 34.3%, III in 50.7%, and IV in 4.5%. 
The tissue samples for the first pathological 
exam were obtained from the primary tumor 
in 98.5% and a systemic metastasis in 1.5%. It 
was obtained by biopsy in 77.9% and came from 
surgery in 22.1%. The tissue samples for the 
second pathological study came from the same 
primary in 80.3%, synchronous contralateral 
primary in 4.6%, local recurrence/metachronous 
ipsilateral primary in 6.1%, metachronous 
contralateral primary in 1.5%, ipsilateral 
regional lymph nodes in 1.5%, synchronous or 
metachronous distant metastases in 6.1%. It was 
obtained by biopsy in 4.5% and by surgery in 
95.5%, (Table 1). The median time between the 
first and second pathology report was 0.55 years, 
interquartile range (IQR): 0.14-0.98 years. 






Primary tumor 98.5% 80.3%
Synchronous contralateral primary tumor - 4.6%
Metachronous ipsilateral primary  
tumor/local recurrence - 6.1%
Metachronous contralateral lesion - 1.5%
Ipsilateral regional lymph nodes recurrence - 1.5%
Systemic metastasis, synchronous  




Between the first and second hormone 
receptor analysis participants received the 
following treatments: chemotherapy 49.2%, 
endocrine therapy 15.4%, both 6.2%, none 
41.5%. Chemotherapy regimens included 
anthracyclines, taxanes, their combination or 
CMF. Endocrine therapy comprised tamoxifen 
or aromatase inhibitors with or without 
gonadotropin-releasing hormone analogs. No 
patient was exposed to palbociclib.
At the baseline, the median of ER was 85% (IQR: 
5.8 -90.0%)), the median of PR was 40% (IQR: 
0.0-80.0%). The distribution according to the 
levels of ER and PR expression at the time of the 
first and the second analyses is shown in Figure 
2. At the baseline, more than half of patients had 
ER in the range between 81% and 100%; 21% of 
patients had a negative status of ER. 
The main results of the comparisons are 
summarized in Table 2. In a two-tailed Wilcoxon 
signed-rank test ER expression at baseline were 
significantly higher than at the time of the second 
analysis (Z=-2.75, r=-0.23, p=0.006). 














































ER and PR expression at the time of the second analysis
Table 2. Quantitative variations in estrogen receptors and progesterone receptors level. Subgroup analysis
Wilcoxon signed-rank test After the Bonferroni  correction (p<0.027)
Subgroup N Z-value p-value r
ER all 68 -2.75 0.006 -0.23 NA


































































PR Age >40 42 -1.76 0.08 -0.19




























ER: Estrogen receptors; PR: Progesterone receptors; S: Significant; NS: Not significant; NA: Not applicable
*N is not large enough for the distribution of the Wilcoxon W statistic to form a normal distribution. Therefore, it is not possible to calculate accurate p-value13
**Data available for 66 patients
For PR a similar trend was observed, but it was not statistically significant (Z=-1.85, r=-0.16, p=0.064). 
Figure 2. Quantitative estrogen receptors and progesterone receptors expression at the time of the first and 
second analysis
ER: estrogen receptors; PR: progesterone receptors
Variations in ER and PR expression according to 
their initial level are shown in Figure 3.
In subgroup analyses, age older than 40 years, 
endocrine therapy and tissue obtained by surgery 
were significantly associated with a decrease in 
the expression of ER, while chemotherapy with 
a reduction of PR (Table 1). When Bonferroni 
correction has been applied, the association 
between chemotherapy and variation in PR level 
was no longer statistically significant. After the 
exclusion of contralateral tumors, results have 
not been changed (not shown). No significant 
difference in the expression of ER at baseline 
between samples obtained by biopsy (median 
80%) or surgery (median 90%) was observed 
in two-tailed Mann-Whitney U-test, (U=354.5, 
p= .50). Similar results were found for PR, 
(median 30% and 60% respectively, U=303.5, 
p=0.23).
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We have examined the relationship between ∆ER 
and the time interval between analyses. When the 
time interval between matched samples was less 
than 0.1 years, the median ∆ER was equal to 0 
percentage points. When it was between 0.1 and 1.0 
years, median ∆ER was -1 percentage points, and 
when it was more than 1.0 years, median ∆ER was 
-13 percentage points. However, the observed trend 
was not statistically significant in the Kruskal-
Wallis test, (H=2.67, p=0.26). Similar results were 
obtained for PR variation, (not shown).
A very strong positive correlation between ER 
and PR expression level at baseline was observed 
in two-tailed Spearman´s rank correlation test 
(rs=0.94, p=0.0048). The degree of correlation 
between ER and PR at the time of the second 
analysis, between ER1 and ER2, and between 
PR1 and PR2 was lesser but still high (rs=0.83, 
p=0.042). Correlation between ∆ER and ∆PR is 
shown in Figure 4.
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Figure 3. Variations in estrogen receptors and progesterone receptors according to the initial level of expression
Figure 4. Correlation between ∆ER and ∆PR
ER: estrogen receptors; PR: progesterone receptors
Finally, we have studied probabilities of transition 
between states of high, intermediate, low and 
null ER expression. Results are displayed as a 
graph in Figure 5. Remaining in the same group 
was the most probable scenario in all classes 
except for the low expression group. From this 
group, no transition to a higher expression class 
was observed. High expression group almost 
always conserved high or intermediate level of 
expression. In the null expression group, staying 
in the same class was, by far, the most common 
scenario, although the transition to a high 
expression class infrequently has occurred. 
Discussion 
We performed a retrospective analysis of 
quantitative variations in hormone receptor 
expression. A statistically significant, small size 
decrease in ER expression was detected. For PR, 
trends similar to those observed for ER have been 
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No statistically significant relationship between 
hormone receptor changes and time interval 
was found.
Age older than 40 years, exposure to endocrine 
therapy and tissue for the first analysis obtained 
from a surgical specimen were significantly 
associated with a decrease in ER expression in 
the univariate analysis. Multivariate analysis 
was not conducted, because the number of 
patients was too small in the subgroups of 
interest. However, in the subgroup of patients 
younger than 41 years, only 7% underwent 
endocrine therapy and only in 13% the tissue 
for the first analysis came from surgery, whereas 
in the subgroup of the older patients the 
respective percentages were near twice as high. 
All this make us suppose that age may not be 
independently related to the changes in the ER 
expression level. 
The tissue sampling method used may 
influence the results of hormone receptors 
determination. In the study by Chen at al, 
although overall concordance was high, core 
needle biopsy specimens were associated with 
higher positive ER and PR rates (2.2% and 3.3% 
respectively) when compared to open excisional 
biopsy. Putative reasons invoked to explain 
the phenomenon were delayed fixation, under-
fixation/over-fixation before IHC and more 
intense staining in the periphery of the tumor 
than in the center, but also random sampling 
error and tumor heterogeneity14. Additionally, 
it can be hypothesized that tissue trauma and 
ischemia, coupled with a surgical procedure, 
may downregulate hormone receptor expression. 
Recently, Gao et al reported a significant impact 
of the sampling method on the regulation of 
gene expression in ER-positive breast cancer. 
However, we failed to identify ESR1/PGR in the 
list of the top-ranked up- and downregulated 
genes provided by authors15. Even if the 
aforementioned considerations are taking into 
account, the exposure to endocrine therapy 
would not be an implausible explanation for the 
decrease in the level of ER, albeit the number of 
patients is small. In line with this, ESR1/PGR 
mRNA expression downregulation in metastatic 
lesion compared with primary tumors has been 
reported16. The clinical significance of the 
described changes is unknown. 
In our study, patients with an absolute ER 
expression of 0% had the lowest probability 
of transition to other states. This fact, in 
combination with a general trend towards a 
lower ER expression, would enable us to put 
forward a hypothesis that the null ER expression 
is a more stable state than others. 
A possible interpretation could be that all 
observed changes in ER expression are a 
result of the lack of the assay reproducibility 
(random error). However, two arguments can be 
opposed to this reasoning. First, the difference 
in ER expression between two time points was 
statistically significant. Second, if the observed 
differences were purely artefactual, similar 
probabilities of transition between groups 
of higher and lower ER expression would be 
expected, whereas, in fact, a sizable difference 
was observed, despite no statistical analyses of 
these data were performed. Shighoko et al17, 
treating ER expression as a binary variable and 
using a Bayesian misclassification correction 
method found that “technical misclassification 
accounted for 53%–83% of the ER discordance 
between synchronous primary cancers and 11%–
25% of ER discordance between metachronous 
cancers”. Also, positive-to-negative changes were 
four times more frequent, than negative-to-
positive in the study by Shighoko et al17. 
We want to stress, that the findings of our study 
are of a hypothesis-generating nature and need 
to be validated in an independent and larger set 
of observations. Ideally, it would be a prospective 
study of a sufficient statistical power, which uses 
a uniform, standardized assay methodology. 
Our study has several limitations. The non-
probabilistic convenience sampling method 
used and the high proportion of eligible patients 
excluded make it prone to the selection bias. 
Figura 5. Probabilities of transition between states of high, 
intermediate, low and null estrogen receptors expression
ER: Estrogen receptors
Nodes are states of high (81%-100%), intermediate (21%-80%), low (1%-20%) and null 
(0%) ER expression. Edges (straight black arrows) stand for probabilities of transition 





















Sample size estimation was not performed and 
the number of patients included was small for 
many analyses. As the primary antibody and 
other relevant elements of the assay were not 
recorded, information bias cannot be discarded.
To our knowledge, this is the first study which 
quantitatively assesses changes in the absolute 
hormone receptors expression and attempts to 
relate them to the treatment exposure.
In conclusion, results of our study suggest that 
even though random error and technical issues 
likely are the main sources of the ER variability, 
results of our study suggest a decrease in 
ER expression, related with tissue sampling 
methodology and/or exposure to endocrine 
therapy.
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